Roma Yumul

2PUBLICATIONS
34CO-AUTHORS
Predictive and prognostic markersGlycoconjugates
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

Sort by Publication Date:
|Aug 24, 2023
SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications.

Robert P Lyon, Mechthild Jonas, Christopher Frantz

|Feb 17, 2023
SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models.

Rebecca Mazahreh, Marsha L Mason, John J Gosink

Pageof 1

Frequent Collaborators

2 joint publications

Christopher J Hale

2 joint publications

Lori Westendorf

1 joint publications

Rebecca Mazahreh

1 joint publications

Marsha L Mason

1 joint publications

John J Gosink

1 joint publications

Devra J Olson

1 joint publications

Robert Thurman

1 joint publications

Thomas A Pires

1 joint publications

Christopher I Leiske

1 joint publications

Markus Carlson

Frequent Collaborators

2 joint publications

Christopher J Hale

2 joint publications

Lori Westendorf

1 joint publications

Rebecca Mazahreh

1 joint publications

Marsha L Mason

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us

Top Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

27.4K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on : Apr 26, 2024

2.8K
See more related videos

Top Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

27.4K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on : Apr 26, 2024

2.8K
See more related videos